Homology Medicines Inc reports results for the quarter ended in March - Earnings Summary

Q32 Bio

15/05/2023 13:00

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 50 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 53 cents per share.
    * Revenue held steady 0% to $802.00 thousand from a year
ago;
analysts expected $1.01 million. 
    * Homology Medicines Inc's reported EPS for the quarter was
a loss
of 50 cents​.
    * The mean earnings estimate of analysts had fallen by
about 9.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Homology Medicines Inc shares had fallen by 4.7% this
quarter and lost 22.1% so far this year.
    * The company reported a quarterly loss of $28.84 million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.53          -0.50          Beat
 Dec. 31 2022      -0.50          -0.60          Missed
 Sep. 30 2022      -0.47          -0.59          Missed
 Jun. 30 2022      -0.56          -0.51          Beat